The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects.
暂无分享,去创建一个
[1] C. Markham,et al. Production of a Parkinson-like syndrome in the cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Behavior, histology, and biochemistry , 1986, Experimental Neurology.
[2] P. Beardsley,et al. Modulation of the discriminative stimulus effects of mu opioid agonists in rats: I. Effects of dopamine D2/3 antagonists , 2004, Behavioural pharmacology.
[3] L. W. Cooke,et al. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. , 1995, The Journal of pharmacology and experimental therapeutics.
[4] G. Skuza,et al. Anxiolytic-like effects of preferential dopamine D3 receptor agonists in an animal model. , 2003, Polish journal of pharmacology.
[5] T. Heffner,et al. 4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties. , 1990, Journal of medicinal chemistry.
[6] V. Calabrese,et al. N‐0923, A novel soluble dopamine D2 agonist in the treatment of parkinsonism , 1998, Movement disorders : official journal of the Movement Disorder Society.
[7] K. Chergui,et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. , 1997, The Journal of pharmacology and experimental therapeutics.
[8] R. Spealman,et al. Discriminative stimulus effects of cocaine in squirrel monkeys: involvement of dopamine receptor subtypes. , 1991, The Journal of pharmacology and experimental therapeutics.
[9] T. Heffner,et al. Synthesis and dopamine agonist properties of (+-)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano [4,3-b]-1,4-oxazin-9-ol and its enantiomers. , 1990, Journal of Medicinal Chemistry.
[10] H. Wikström,et al. Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand. , 1993, European journal of pharmacology.
[11] J. Macher,et al. Dopamine D3 receptor gene: organization, transcript variants, and polymorphism associated with schizophrenia. , 1996, American journal of medical genetics.
[12] R. Mach,et al. Characterization of 125I‐IABN, a novel azabicyclononane benzamide selective for D2‐like dopamine receptors , 2000, Synapse.
[13] F. Boeckler,et al. Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists. , 2005, Journal of medicinal chemistry.
[14] W. Im,et al. Identification of transmembrane regions critical for ligand binding to the human D3 dopamine receptor using various D3/D1 transmembrane chimeras. , 1998, Molecular pharmacology.
[15] P. Seeman,et al. New dopamine receptor, D2(Longer), with unique TG splice site, in human brain. , 2000, Brain research. Molecular brain research.
[16] P. Jeffrey,et al. Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase , 2001, Xenobiotica; the fate of foreign compounds in biological systems.
[17] J. Witkin,et al. Protection against Cocaine Toxicity in Mice by the Dopamine D3/D2 Agonist R-(+)-trans-3,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907] , 2004, Journal of Pharmacology and Experimental Therapeutics.
[18] Jonathan A Javitch,et al. Mapping the binding-site crevice of the dopamine D2 receptor by the substituted-cysteine accessibility method , 1995, Neuron.
[19] A. Carlsson,et al. (+)-AJ 76 and (+)-UH 232: Central stimulants acting as preferential dopamine autoreceptor antagonists , 1986, Naunyn-Schmiedeberg's Archives of Pharmacology.
[20] P. Beardsley,et al. Modulation of the locomotor activating effects of the noncompetitive NMDA receptor antagonist MK801 by dopamine D2/3 receptor agonists in mice , 2004, Pharmacology Biochemistry and Behavior.
[21] Philip Seeman,et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine , 1991, Nature.
[22] M. Muenter,et al. Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.
[23] S. Cooper,et al. The effects of 7-OH-DPAT, quinpirole and raclopride on licking for sucrose solutions in the non-deprived rat , 2003, Behavioural Pharmacology.
[24] Bryan L Roth,et al. G-protein-coupled receptors at a glance , 2003, Journal of Cell Science.
[25] H. Wikström,et al. Structural analogues of 5-OMe-BPAT: synthesis and interactions with dopamine D2, D3, and serotonin 5-HT1A receptors. , 1999, Bioorganic & medicinal chemistry.
[26] J. Schneider,et al. Changes in striatal dopamine D3 receptor regulation during expression of and recovery from MPTP-induced parkinsonism , 2001, Brain Research.
[27] P. Gmeiner,et al. Ex-chiral pool synthesis and receptor binding studies of 4-substituted prolinol derivatives , 2003 .
[28] M. Scheideler,et al. cis- and trans-2,3,3a,4,5,9b-Hexahydro-1H-benz[e]indoles: synthesis and evaluation of dopamine D2, and D3 receptor binding affinity , 1999 .
[29] J. Palacios,et al. High resolution separation methods for the determination of intact human erythropoiesis stimulating agents. A review. , 2012, Analytica chimica acta.
[30] Gerhard Hessler,et al. Drug Design Strategies for Targeting G‐Protein‐Coupled Receptors , 2002, Chembiochem : a European journal of chemical biology.
[31] M. Millan,et al. Involvement of dopamine D2/D3 receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells , 2004, Experimental Neurology.
[32] Harald Hübner,et al. Analogues of FAUC 73 revealing new insights into the structural requirements of nonaromatic dopamine D3 receptor agonists. , 2004, Bioorganic & medicinal chemistry.
[33] P. Sokoloff,et al. Disruption of nicotine conditioning by dopamine D3 receptor ligands , 2003, Molecular Psychiatry.
[34] G. F. Koob,et al. Pretreatment with the dopamine agonist 7‐OH‐DPAT shifts the cocaine self‐administration dose‐effect function to the left under different schedules in the rat , 1995, Behavioural pharmacology.
[35] J. Ballesteros,et al. Residues in the seventh membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site crevice. , 1996, Biochemistry.
[36] P. Molinoff,et al. Characterization of binding sites for [125I]R(+)trans-7-OH-PIPAT in rat brain , 1994, Naunyn-Schmiedeberg's Archives of Pharmacology.
[37] I. Tulloch. Pharmacologic profile of ropinirole , 1997, Neurology.
[38] J. Ballesteros,et al. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. , 2001, Molecular pharmacology.
[39] M. Martres,et al. The third dopamine receptor (D3) as a novel target for antipsychotics. , 1992, Biochemical pharmacology.
[40] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.
[41] A. Zapata,et al. D3 receptor ligands modulate extracellular dopamine clearance in the nucleus accumbens , 2002, Journal of neurochemistry.
[42] H. Szechtman,et al. Effect of nicotine on quinpirole-induced checking behavior in rats: implications for obsessive-compulsive disorder , 2002, Biological Psychiatry.
[43] Marcus Elstner,et al. The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. , 2004, Journal of molecular biology.
[44] J. Kemp,et al. Functional expression of human D3 dopamine receptors in differentiated neuroblastoma × glioma NG108–15 cells , 1994, British journal of pharmacology.
[45] T. Heffner,et al. Thiazoloindans and thiazolobenzopyrans: a novel class of orally active central dopamine (partial) agonists. , 2000, Journal of medicinal chemistry.
[46] A. Carlsson,et al. The dopamine D3-receptor: A postsynaptic receptor inhibitory on rat locomotor activity , 2005, Journal of Neural Transmission / General Section JNT.
[47] M. P. Turpin,et al. A novel series of arylpiperazines with high affinity and selectivity for the dopamine D3 receptor , 1995 .
[48] P. Seeman,et al. Multiple dopamine D4 receptor variants in the human population , 1992, Nature.
[49] Y. Lecrubier,et al. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. , 1995, The American journal of psychiatry.
[50] J. Javitch,et al. Residues in the fifth membrane-spanning segment of the dopamine D2 receptor exposed in the binding-site crevice. , 1995, Biochemistry.
[51] J. Meador-Woodruff,et al. Linking the Family of D2 Receptors to Neuronal Circuits in Human Brain: Insights into Schizophrenia , 1997, Neuropsychopharmacology.
[52] C. Heidbreder,et al. Gradient of dopamine responsiveness to dopamine receptor agonists in subregions of the rat nucleus accumbens. , 2003, European journal of pharmacology.
[53] H. Wikström,et al. Characterization of the effect of dopamine D3 receptor stimulation on locomotion and striatal dopamine levels , 1997, Brain Research.
[54] S. Hjorth,et al. Monophenolic 2-(dipropylamino)indans and related compounds: central dopamine-receptor stimulating activity. , 1981, Journal of Medicinal Chemistry.
[55] M. Millan,et al. The novel antagonist, S33084, and GR218,231 interact selectively with cloned and native, rat dopamine D(3) receptors as compared with native, rat dopamine D(2) receptors. , 2000, European journal of pharmacology.
[56] G. Schingnitz,et al. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. , 1992, European journal of pharmacology.
[57] S. Konitsiotis,et al. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. , 1997, The Journal of pharmacology and experimental therapeutics.
[58] P. Goldman-Rakic,et al. Localization of dopamine D4 receptors in GABAergic neurons of the primate brain , 1996, Nature.
[59] J. Ginos,et al. Intravenous self-administration of dopamine receptor agonists by rhesus monkeys. , 1984, The Journal of pharmacology and experimental therapeutics.
[60] J. Cannon. Structure-activity relationships of dopamine agonists. , 1983, Annual review of pharmacology and toxicology.
[61] A. Lieberman,et al. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study , 1997, Neurology.
[62] J. Ballesteros,et al. The first transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle. , 2000, Biochemistry.
[63] R. Mach,et al. Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders. , 2003, Current pharmaceutical design.
[64] Susan R. George,et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1 , 1991, Nature.
[65] M. Millan,et al. [3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.
[66] A Carlsson,et al. A Paradigm Shift in Brain Research , 2001, Science.
[67] SB-277011 GlaxoSmithKline. , 2001, Current opinion in investigational drugs.
[68] M. Cador,et al. Differential effects of dopaminergic agents on locomotor sensitisation and on the reinstatement of cocaine-seeking and food-seeking behaviour , 2003, Psychopharmacology.
[69] M. Miller,et al. Assessment of the discriminative stimulus effects of the D3 dopamine antagonist PNU-99194A in rats: comparison with psychomotor stimulants. , 1997, Behavioural pharmacology.
[70] H. Wikström,et al. Motor effects of a dopamine stabilizer (GMC1111) in primate models of Parkinson and hemiparkinsonism. , 2003, European journal of pharmacology.
[71] T. Sotnikova,et al. Effects of intrastriatal infusion of D2 and D3 dopamine receptor preferring antagonists on dopamine release in rat dorsal striatum (in vivo microdialysis study). , 2001, Pharmacological research.
[72] D. Grandy,et al. Molecular diversity of the dopamine receptors. , 1993, Annual review of pharmacology and toxicology.
[73] P. Gmeiner,et al. Parallel synthesis and biological screening of dopamine receptor ligands taking advantage of a click chemistry based BAL linker. , 2005, Journal of combinatorial chemistry.
[74] C. Schneider,et al. Dopamine autoreceptor agonists: resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analogue of apomorphine. , 1987, Journal of medicinal chemistry.
[75] M. Millan,et al. Tetracyclic analogues of [+]-S 14297: Synthesis and determination of affinity and selectivity at cloned human dopamine D3 vs D2 receptors , 1997 .
[76] R. Spealman. Dopamine D3 receptor agonists partially reproduce the discriminative stimulus effects of cocaine in squirrel monkeys. , 1996, The Journal of pharmacology and experimental therapeutics.
[77] Maria Jesus Martin,et al. The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003 , 2003, Nucleic Acids Res..
[78] M. Nader,et al. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. , 2005, Journal of medicinal chemistry.
[79] Yoshinori Shichida,et al. Functional role of internal water molecules in rhodopsin revealed by x-ray crystallography , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[80] A. Newman,et al. Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype. , 2001, Journal of medicinal chemistry.
[81] D. Evans,et al. Dopaminergic and serotonergic activities of imidazoquinolinones and related compounds. , 1992, Journal of medicinal chemistry.
[82] R. Spealman,et al. Dopamine D1- and D2-like receptor mechanisms in relapse to cocaine-seeking behavior: effects of selective antagonists and agonists. , 2000, The Journal of pharmacology and experimental therapeutics.
[83] H. Wikström,et al. Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity. , 1996, Journal of medicinal chemistry.
[84] J. Kebabian,et al. Multiple receptors for dopamine , 1979, Nature.
[85] Lei Shi,et al. The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. , 2002, Annual review of pharmacology and toxicology.
[86] P. Gmeiner,et al. Enantio- and diastereocontrolled dopamine D1, D2, D3 and D4 receptor binding of N-(3-pyrrolidinylmethyl)benzamides synthesized from aspartic acid. , 1999, Bioorganic & medicinal chemistry letters.
[87] R. Todd,et al. Characterization of the human dopamine D3 receptor expressed in transfected cell lines. , 1994, European journal of pharmacology.
[88] M. Zarrindast,et al. Morphine state-dependent learning: sensitization and interactions with dopamine receptors. , 2004, European journal of pharmacology.
[89] N Rodenhuis,et al. Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907). , 2000, Journal of medicinal chemistry.
[90] P. Sokoloff,et al. Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence 1 Published on the World Wide Web on 24 November 1997. 1 , 1998, Brain Research Reviews.
[91] C Dacquet,et al. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. , 1995, The Journal of pharmacology and experimental therapeutics.
[92] M. Martres,et al. Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. , 1992, European journal of pharmacology.
[93] D. Wong,et al. Resolution and absolute configuration of an ergoline-related dopamine agonist, trans-4,4a,5,6,7,8,8a,9-Octahydro-5-propyl-1H(or 2H)-pyrazolo[3,4-g]quinoline. , 1983, Journal of medicinal chemistry.
[94] R. Vaccaro,et al. Dissociation in the effects of the D2/D3 dopaminergic agonist quinpirole on drinking and on vasopressin levels in the rat , 2002, Neuroscience Letters.
[95] Stephen J. Johnson,et al. 4-bromo-1-methoxy-N-[2-(4-aryl-1-piperazinyl)ethyl]-2-naphthalenecarboxamides: Selective dopamine D3 receptor partial agonists , 1996 .
[96] J. Maj,et al. Locomotor hypoactivity and motor disturbances--behavioral effects induced by intracerebellar microinjections of dopaminergic DA-D2/D3 receptor agonists. , 2001, Polish journal of pharmacology.
[97] S. Hjorth,et al. Monophenolic octahydrobenzo[f]quinolines: central dopamine- and serotonin-receptor stimulating activity. , 1982, Journal of medicinal chemistry.
[98] H. Wikström,et al. Characterization of binding of [3H]PD 128907, a selective dopamine D3 receptor agonist ligand, to CHO-K1 cells. , 1995, Life sciences.
[99] P. Sokoloff,et al. A functional test identifies dopamine agonists selective for D3 versus D2 receptors. , 1995, Neuroreport.
[100] J. Hagan,et al. The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. , 1998, Journal of medicinal chemistry.
[101] P. Seeman,et al. Dopamine D4 receptors elevated in schizophrenia , 1993, Nature.
[102] G. Vauquelin,et al. Autoradiographic distribution of D3-type dopamine receptors in human brain using [3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin , 1994, Brain Research.
[103] C. Tamminga,et al. D2-Family receptor distribution in human postmortem tissue: an autoradiographic study , 1995, Neuroreport.
[104] I. Lucki,et al. Quantitative autoradiographic mapping of rat brain dopamine D3 binding with [(125)I]7-OH-PIPAT: evidence for the presence of D3 receptors on dopaminergic and nondopaminergic cell bodies and terminals. , 2000, The Journal of pharmacology and experimental therapeutics.
[105] P. Sokoloff,et al. Identification of the dopamine autoreceptor in the guinea‐pig retina as D2 receptor using novel subtype‐selective antagonists , 2001, British journal of pharmacology.
[106] W. Im,et al. Agonist-induced [35S]GTPγS binding in the membranes of Spodoptera frugiperda insect cells expressing the human D3 dopamine receptor , 1997, Neuroscience Letters.
[107] M. Millan,et al. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents. , 1997, The Journal of pharmacology and experimental therapeutics.
[108] M. Martres,et al. [Gene cloning of human dopaminergic D3 receptor and identification of its chromosome]. , 1990, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.
[109] H. Sahraei,et al. Involvement of dopamine D2 receptors of the central amygdala on the acquisition and expression of morphine-induced place preference in rat , 2002, Pharmacology Biochemistry and Behavior.
[110] Design and synthesis of novel 2,3-dihydro-1H-isoindoles with high affinity and selectivity for the dopamine D3 receptor. , 2001, Bioorganic & medicinal chemistry letters.
[111] Torsten Kuwert,et al. Synthesis and radioiodination of selective ligands for the dopamine D3 receptor subtype. , 2004, Bioorganic & medicinal chemistry letters.
[112] M. Hamon,et al. Effects of a Dopamine D3 Receptor Ligand, BP 897, on Acquisition and Expression of Food-, Morphine-, and Cocaine-induced Conditioned Place Preference, and Food-seeking Behavior in Rats , 2003, Neuropsychopharmacology.
[113] B. Ferger,et al. The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study , 2000, Brain Research.
[114] J. Schneider,et al. Neuroprotective effects of pramipexole in young and aged MPTP-treated mice , 2001, Brain Research.
[115] Robert H. Mach,et al. Synthesis, in vitro dopamine D2 and D3 receptor binding and quantitative structure-activity studies on substituted 2,3-dimethoxy-N-(1- benzyl-4-piperidinyl)benzamides and related compounds , 1999 .
[116] M. Papp,et al. S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: III. Actions in Models of Potential Antidepressive and Anxiolytic Activity in Comparison with Ropinirole , 2004, Journal of Pharmacology and Experimental Therapeutics.
[117] M. Knowles,et al. Expression and pharmacological characterization of the human D3 dopamine receptor. , 1994, The Journal of pharmacology and experimental therapeutics.
[118] G. Phillips,et al. Blockade of sensitisation-induced facilitation of appetitive conditioning by post-session intra-amygdala nafadotride , 2002, Behavioural Brain Research.
[119] H. Wikström,et al. Synthesis and Pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT. , 1999, Bioorganic & medicinal chemistry.
[120] Y. Lecrubier,et al. Treatment of Negative Symptoms in Schizophrenia with Amisulpride , 1995, British Journal of Psychiatry.
[121] G. Gessa,et al. Apomorphine-induced penile erection and yawning: site of action in brain , 1987, Brain Research.
[122] R. Depoortère,et al. Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice , 1999, Neuropharmacology.
[123] J. Hieble,et al. 4-[2-(Di-n-propylamino)ethyl]-2(3H)-indolone: a prejunctional dopamine receptor agonist. , 1985, Journal of medicinal chemistry.
[124] J. Welge,et al. The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine , 2000, Brain Research.
[125] H. Wikström,et al. Further characterization of structural requirements for ligands at the dopamine D(2) and D(3) receptor: exploring the thiophene moiety. , 2002, Journal of medicinal chemistry.
[126] A. Horn,et al. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF THE HEXAHYDRO-4H-NAPHTH[1,2B][1,4]-OXAZINES - A NEW SERIES OF POTENT DOPAMINE RECEPTOR AGONISTS , 1985 .
[127] Vincenzo Tortorella,et al. Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D(3) receptor ligands. , 2002, Journal of medicinal chemistry.
[128] D. Jackson,et al. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. , 1993, Molecular pharmacology.
[129] J. Schneider,et al. Changes in striatal dopamine D2 receptors in relation to expression of and recovery from experimental parkinsonism , 2000, Brain Research.
[130] G. Gonnet,et al. Exhaustive matching of the entire protein sequence database. , 1992, Science.
[131] Lei Shi,et al. The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[132] R. Depoortère,et al. Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists , 1999, Neuropharmacology.
[133] H. Shill,et al. Continuous Transdermal Dopaminergic Stimulation in Advanced Parkinson's Disease , 2001, Clinical neuropharmacology.
[134] B. Levant,et al. The D3 dopamine receptor in cellular and organismal function , 1998, Psychopharmacology.
[135] P. Gmeiner,et al. Phenyloxazoles and phenylthiazoles as benzamide bioisosteres: synthesis and dopamine receptor binding profiles. , 2000, Bioorganic & medicinal chemistry letters.
[136] T. Uzbay,et al. Bromocriptine and quinpirole, but not 7-OH-DPAT or SKF 38393, potentiate the inhibitory effect of L-NAME on ethanol-induced locomotor activity in mice , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.
[137] P. Sokoloff,et al. Two Intracellular Signaling Pathways for the Dopamine D3 Receptor: Opposite and Synergistic Interactions with Cyclic AMP , 1997, Journal of neurochemistry.
[138] Thomas Boraud,et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function , 2003, Nature Medicine.
[139] J. Rubin,et al. Novel cyclohexyl amides as potent and selective D3 dopamine receptor ligands , 1997 .
[140] B. Sommer,et al. The dopamine D2 receptor: two molecular forms generated by alternative splicing. , 1989, The EMBO journal.
[141] R. Wise,et al. Amphetamine-type reinforcement by dopaminergic agonists in the rat , 1978, Psychopharmacology.
[142] P. J. Larsen,et al. The preferential dopamine D3 receptor agonist cis-8-OH-PBZI induces limbic Fos expression in rat brain. , 1997, European journal of pharmacology.
[143] P. Sokoloff,et al. The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches , 1995, European Neuropsychopharmacology.
[144] B. Levant. The D3 dopamine receptor: neurobiology and potential clinical relevance. , 1997, Pharmacological reviews.
[145] Rudie Kortekaas,et al. In vivo Binding Behavior of Dopamine Receptor Agonist (+)−PD 128907 and Implications for the “Ceiling Effect” in Endogenous Competition Studies with [11C]Raclopride—a Positron Emission Tomography Study in Macaca mulatta , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[146] A. Schapira,et al. Pramipexole protects against apoptotic cell death by non‐dopaminergic mechanisms , 2004, Journal of neurochemistry.
[147] A. Cools,et al. Excitation-mediating and inhibition-mediating dopamine-receptors: A new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data , 1976, Psychopharmacologia.
[148] J. Witkin,et al. Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections. , 1991, The Journal of pharmacology and experimental therapeutics.
[149] Stanley J Watson,et al. Dopamine Receptor mRNA Expression in Human Striatum and Neocortex , 1996, Neuropsychopharmacology.
[150] J. Bockaert,et al. Molecular tinkering of G protein‐coupled receptors: an evolutionary success , 1999, The EMBO journal.
[151] R. Todd,et al. Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. , 1994, The Journal of pharmacology and experimental therapeutics.
[152] B. Everitt,et al. Attenuation of Cue-Controlled Cocaine-Seeking by a Selective D3 Dopamine Receptor Antagonist SB-277011-A , 2003, Neuropsychopharmacology.
[153] G Vriend,et al. WHAT IF: a molecular modeling and drug design program. , 1990, Journal of molecular graphics.
[154] Zhen Yan,et al. D3 Dopamine Autoreceptors Do Not Activate G-Protein-Gated Inwardly Rectifying Potassium Channel Currents in Substantia Nigra Dopamine Neurons , 2003, The Journal of Neuroscience.
[155] K. Neve,et al. Activation of type II adenylate cyclase by D2 and D4 but not D3 dopamine receptors. , 1997, Molecular pharmacology.
[156] K. Svensson,et al. PNU‐99194A: A Preferential Dopamine D3 Receptor Antagonist , 1998 .
[157] A. Jaton,et al. Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives with functionalized N-alkyl substituents. , 1986, Journal of medicinal chemistry.
[158] K. Denicoff,et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study , 2004, Biological Psychiatry.
[159] K. Cunningham,et al. Dopamine D1 and D2 mediation of the discriminative stimulus properties ofd-amphetamine and cocaine , 2005, Psychopharmacology.
[160] E. Domino,et al. Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys. , 1993, The Journal of pharmacology and experimental therapeutics.
[161] M. Kleven,et al. Dopamine D2 receptors play a role in the (-)-apomorphine-like discriminative stimulus effects of (+)-PD 128907. , 1997, European journal of pharmacology.
[162] D. Sibley,et al. [3H]7-OH-DPAT is capable of labeling dopamine D2 as well as D3 receptors. , 1995, European journal of pharmacology.
[163] M. Millan,et al. Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra , 2001, Brain Research.
[164] C. Chidester,et al. Comparison of 5-HT1A and dopamine D2 pharmacophores. X-ray structures and affinities of conformationally constrained ligands. , 1993, Journal of medicinal chemistry.
[165] K. Svensson,et al. The preferential dopamine autoreceptor antagonist (+)-UH232 antagonizes the positive reinforcing effects of cocaine and d-amphetamine in the ICSS paradigm , 1994, Pharmacology Biochemistry and Behavior.
[166] M. Millan,et al. S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: I. Cellular, Electrophysiological, and Neurochemical Profile in Comparison with Ropinirole , 2004, Journal of Pharmacology and Experimental Therapeutics.
[167] H. Kung,et al. Synthesis and optical resolution of (R)- and (S)-trans-7-Hydroxy-2-[N-propyl-N-(3'-iodo-2'-propenyl)amino]tetralin: a new D3 dopamine receptor ligand. , 1993, Journal of medicinal chemistry.
[168] R. North,et al. D2, D3, and D4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes. , 1996, Molecular pharmacology.
[169] T. Petcher,et al. Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine. , 1985, Journal of medicinal chemistry.
[170] Harald Hübner,et al. Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists. , 2002, Journal of medicinal chemistry.
[171] D. Hall,et al. Pharmacological analysis of dopamine stimulation of [35S]‐GTPγS binding via human D2short and D2long dopamine receptors expressed in recombinant cells , 1996, British journal of pharmacology.
[172] J. Joyce. Multiple dopamine receptors and behavior , 1983, Neuroscience & Biobehavioral Reviews.
[173] M. Millan,et al. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. , 2000, The Journal of pharmacology and experimental therapeutics.
[174] J. Welge,et al. 7-OH-DPAT and PD 128907 Selectively Activate the D3 Dopamine Receptor in a Novel Environment , 2003, Neuropsychopharmacology.
[175] Kevin J Black,et al. A possible substrate for dopamine-related changes in mood and behavior: Prefrontal and limbic effects of a D3-preferring dopamine agonist , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[176] P. Soubrié,et al. Blockade by the Cannabinoid CB1 Receptor Antagonist, Rimonabant (SR141716), of the Potentiation by Quinelorane of Food-Primed Reinstatement of Food-Seeking Behavior , 2004, Neuropsychopharmacology.
[177] H. Kung,et al. Synthesis of (.+-.)-2'-trans-7-hydroxy-2-[N-(3'-iodo-2'-propenyl)-N-n-propylamino]tetralin (trans-7-OH-PIPAT): a new D3 dopamine receptor ligand , 1993 .
[178] J. Schwartz,et al. Parallel synthesis and dopamine D3/D2 receptor screening of novel {4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}carboxamides. , 2005, Bioorganic & Medicinal Chemistry.
[179] J. Joyce,et al. Developmental regulation of expression of the D3 dopamine receptor in rat nucleus accumbens and islands of Calleja. , 1999, The Journal of pharmacology and experimental therapeutics.
[180] F. Boeckler,et al. Fancy bioisosteres: synthesis, SAR, and pharmacological investigations of novel nonaromatic dopamine D3 receptor ligands. , 2005, Bioorganic & medicinal chemistry.
[181] M. Millan,et al. S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole , 2004, Journal of Pharmacology and Experimental Therapeutics.
[182] P. Sokoloff,et al. The preferential dopamine D3 receptor ligand, (+)-UH232, is a partial agonist. , 1995, European journal of pharmacology.
[183] P. Strange,et al. Comparison of the ability of dopamine receptor agonists to inhibit forskolin-stimulated adenosine 3'5'-cyclic monophosphate (cAMP) accumulation via D2L (long isoform) and D3 receptors expressed in Chinese hamster ovary (CHO) cells. , 1999, Biochemical pharmacology.
[184] P. Strange,et al. Role of Conserved Serine Residues in the Interaction of Agonists with D3 Dopamine Receptors , 1999, Journal of neurochemistry.
[185] M. Millan,et al. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. , 1998, The Journal of pharmacology and experimental therapeutics.
[186] A. Carlsson,et al. (S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists. , 1993, Journal of medicinal chemistry.
[187] M. Martres,et al. Opposing Roles for Dopamine D2 and D3 Receptors on Neurotensin mRNA Expression in Nucleus Accumbens , 1994, The European journal of neuroscience.
[188] P. Houck,et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. , 2002, Bipolar disorders.
[189] I. Gyertyán,et al. Targeting the dopamine D3 receptor cannot influence continuous reinforcement cocaine self-administration in rats , 2003, Brain Research Bulletin.
[190] A. Newman,et al. N-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D(3) receptor antagonists. , 2003, Bioorganic & medicinal chemistry letters.
[191] P. Sokoloff,et al. Development of Novel 1,2,3,4‐Tetrahydroisoquinoline Derivatives and Closely Related Compounds as Potent and Selective Dopamine D3 Receptor Ligands , 2004, Chembiochem : a European journal of chemical biology.
[192] T. Yanagihara,et al. Expression of the D3 dopamine receptor gene and a novel variant transcript generated by alternative splicing in human peripheral blood lymphocytes. , 1993, Biochemical and biophysical research communications.
[193] K. Thewlis,et al. Novel 1,2,3,4-tetrahydroisoquinolines with high affinity and selectivity for the dopamine D3 receptor. , 1999, Bioorganic & medicinal chemistry letters.
[194] P. Molinoff,et al. Characterization of [125I](R)-trans-7-hydroxy-2-[N-propyl-N-(3'-iodo-2'-propenyl)amino] tetralin binding to dopamine D3 receptors in rat olfactory tubercle. , 1994, The Journal of pharmacology and experimental therapeutics.
[195] P. Beardsley,et al. The modulatory actions of dopamine D2/3 agonists and antagonists on the locomotor-activating effects of morphine and caffeine in mice , 2003, Pharmacology Biochemistry and Behavior.
[196] P. Mcgonigle,et al. Ontogeny of dopamine D3 receptors in the nucleus accumbens of the rat , 1997, Neuroscience Letters.
[197] J. Hagan,et al. Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat. , 2000, Journal of medicinal chemistry.
[198] C. Tamminga,et al. Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia , 1998, Journal of Neural Transmission.
[199] S. Happe,et al. Role of Dopamine Receptor Agonists in the Treatment of Restless Legs Syndrome , 2004, CNS Drugs.
[200] L. Stein,et al. The D1 agonists SKF 82958 and SKF 77434 are self-administered by rats , 1992, Brain Research.
[201] A. Carlsson,et al. Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans. , 2001, Journal of medicinal chemistry.
[202] L. Coolen,et al. Altered Behavioral Response to Dopamine D3 Receptor Agonists 7-OH-DPAT and PD 128907 Following Repetitive Amphetamine Administration , 2003, Neuropsychopharmacology.
[203] C. Proud,et al. Activation of Microtubule‐Associated Protein Kinase (Erk) and p70 S6 Kinase by D2 Dopamine Receptors , 1998, Journal of neurochemistry.
[204] Harald Hübner,et al. Practical ex-chiral-pool methodology for the synthesis of dopaminergic tetrahydroindoles , 2004 .
[205] G. Mckenzie,et al. Synthesis and dopaminergic activity of (+/-)-, (+)-, and (-)-2-dipropylamino-5-hydroxy-1,2,3,4-tetrahydronaphthalene. , 1976, Journal of medicinal chemistry.
[206] D. Evans,et al. Dopamine D2 receptor binding properties of [3H]U-86170, a dopamine receptor agonist. , 1991, European journal of pharmacology.
[207] S. Hjorth,et al. Resolved monophenolic 2-aminotetralins and 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines: structural and stereochemical considerations for centrally acting pre- and postsynaptic dopamine-receptor agonists. , 1985, Journal of Medicinal Chemistry.
[208] J. Clemens,et al. Bicyclic and tricyclic ergoline partial structures. Rigid 3-(2-aminoethyl)pyrroles and 3- and 4-(2-aminoethyl)pyrazoles as dopamine agonists. , 1980, Journal of medicinal chemistry.
[209] G. Riley,et al. Novel 2,5-disubstituted-1H-pyrroles with high affinity for the dopamine D3 receptor : N-benzyl modifications , 1997 .
[210] Xueliang Fang,et al. Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. , 2003, Journal of medicinal chemistry.
[211] J. Ballesteros,et al. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .
[212] P. Sokoloff,et al. D2/D3 Dopamine Receptor Heterodimers Exhibit Unique Functional Properties* , 2001, The Journal of Biological Chemistry.
[213] T. Kenakin,et al. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. , 1995, Trends in pharmacological sciences.
[214] D C Teller,et al. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). , 2001, Biochemistry.
[215] G. Skuza,et al. Anxiolytic- and antidepressant-like effects of 7-OH-DPAT, preferential dopamine D3 receptor agonist, in rats. , 2004, Polish journal of pharmacology.
[216] D. Evans,et al. Pre- and postsynaptic dopaminergic activities of U-86170F , 1991, Naunyn-Schmiedeberg's Archives of Pharmacology.
[217] J. Clemens,et al. Degree of Selectivity of Pergolide as an Agonist at Presynaptic Versus Postsynaptic Dopamine Receptors: Implications for Prevention or Treatment of Tardive Dyskinesia , 1982, Journal of clinical psychopharmacology.
[218] B. Ferger,et al. Neurochemical findings in the MPTP model of Parkinson's disease , 2001, Journal of neural transmission.
[219] B. Everitt,et al. D3 receptor test in vitro predicts decreased cocaine self‐administration in rats , 1997, Neuroreport.
[220] P. Gmeiner,et al. Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D(3) subtype. , 2000, Journal of medicinal chemistry.
[221] P. Sokoloff,et al. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. , 1999, European journal of pharmacology.
[222] S. Senogles,et al. D3 dopamine receptor activates phospholipase D through a pertussis toxin-insensitive pathway , 2004, Neuroscience Letters.
[223] E. Novellino,et al. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. , 2003, Journal of medicinal chemistry.
[224] J. van der Weide,et al. Synthesis and pharmacology of trans-4-n-propyl-3,4,4a,10b-tetrahydro-2H,5H-1-benzopyrano[4,3-b ]-1,4-oxazin-7- and -9-ols: the significance of nitrogen pKa values for central dopamine receptor activation. , 1988, Journal of medicinal chemistry.
[225] P. Strange,et al. Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors , 1997, British journal of pharmacology.
[226] G. Riley,et al. Heterocyclic analogues of 2-aminotetralins with high affinity and selectivity for the dopamine D3 receptor. , 1999, Bioorganic & medicinal chemistry letters.
[227] P. Sokoloff,et al. Selective Expression of Dopamine D3 Receptor mRNA in Proliferative Zones during Embryonic Development of the Rat Brain , 1997, The Journal of Neuroscience.
[228] N. Robakis,et al. Molecular cloning and characterization of the mouse dopamine D3 receptor gene: an additional intron and an mRNA variant. , 1995, DNA and cell biology.
[229] A. Schapira. Neuroprotection and dopamine agonists , 2002, Neurology.
[230] G. Höfner,et al. Synthesis, Pharmacological Investigation and Computational Studies on a Tricyclic Ergoline Analog with Selective Dopamine Autoreceptor Activity , 1995, Archiv der Pharmazie.
[231] J. Hagan,et al. Acute and chronic administration of the selective D(3) receptor antagonist SB-277011-A alters activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. , 2000, The Journal of pharmacology and experimental therapeutics.
[232] M. Martres,et al. Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. , 1994, European journal of pharmacology.
[233] P. Sokoloff,et al. Role of dopamine D3 receptors in thermoregulation: a reappraisal , 2000, Neuroreport.
[234] G. Koob,et al. The dopamine receptor agonist 7-OH-DPAT modulates the acquisition and expression of morphine-induced place preference. , 1995, European journal of pharmacology.
[235] J. Hagan,et al. Selective Antagonism at Dopamine D3 Receptors Enhances Monoaminergic and Cholinergic Neurotransmission in the Rat Anterior Cingulate Cortex , 2003, Neuropsychopharmacology.
[236] Bernd Saletu,et al. Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine. , 1994 .
[237] M. Millan,et al. G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: A guanosine-5'-O-(3-[35S]thio)- triphosphate binding and antibody study. , 1999, Molecular pharmacology.
[238] M. Millan,et al. Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist. , 1999, Bioorganic & medicinal chemistry letters.
[239] P. Gmeiner,et al. Dopaminergic 7-aminotetrahydroindolizines: ex-chiral pool synthesis and preferential D3 receptor binding. , 2001, Bioorganic & medicinal chemistry letters.
[240] P. Bonaventure,et al. Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study , 1996, The Histochemical Journal.
[241] J. Hubble,et al. Pre‐clinical studies of pramipexole: clinical relevance , 2000, European journal of neurology.
[242] Y. Wong,et al. Gz signaling: emerging divergence from Gi signaling , 2001, Oncogene.
[243] Sabine Borwege,et al. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor , 2004, BMC Biology.
[244] Piercey Mf. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. , 1998 .
[245] I. Gyertyán,et al. Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011 , 2004, Behavioural pharmacology.
[246] Novel 2,3,4,5-tetrahydro-1H-3-benzazepines with high affinity and selectivity for the dopamine D3 receptor. , 2000, Bioorganic & medicinal chemistry letters.
[247] J. Hagan,et al. Selective Antagonism at Dopamine D3 Receptors Prevents Nicotine-Triggered Relapse to Nicotine-Seeking Behavior , 2003, Neuropsychopharmacology.
[248] G. Riley,et al. Novel 2,5-disubstituted-1H-pyrroles with high affinity for the dopamine D3 receptor , 1996 .
[249] L. Bristow,et al. Discriminative stimulus properties of the putative dopamine D3 receptor agonist, (+)-PD 128907: role of presynaptic dopamine D2 autoreceptors , 1998, Neuropharmacology.
[250] J. Hagan,et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. , 2000, The Journal of pharmacology and experimental therapeutics.
[251] P. Riederer,et al. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum , 2003, Journal of Neural Transmission.
[252] P. Molinoff,et al. Lack of Discrimination by Agonists for D2 and D3 Dopamine Receptors , 1995, Neuropsychopharmacology.
[253] J. Yuan,et al. NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists. , 1998, Bioorganic & medicinal chemistry letters.
[254] G. N. Bancroft,et al. Binding of [3H]PD 128907, a Putatively Selective Ligand for the D3 Dopamine Receptor, in Rat Brain: A Receptor Binding and Quantitative Autoradiographic Study , 1998, Neuropsychopharmacology.
[255] J. Joyce. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. , 2001, Pharmacology & therapeutics.
[256] G. Riley,et al. Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor. , 2000, European journal of pharmacology.
[257] D. Kocjan. On the interaction of the aromatic part of dopaminergic agonists with the receptor. , 1994, Journal of medicinal chemistry.
[258] D. Wong,et al. Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity. , 1989, Journal of medicinal chemistry.
[259] D. Grandy,et al. Dopamine Receptor Gene Expression in the Human Medial Temporal Lobe , 1994, Neuropsychopharmacology.
[260] J. Feldon,et al. Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity by the novel selective dopamine D3-receptor partial agonist FAUC 329 predominantly in the nucleus accumbens of mice. , 2003, Biochemical pharmacology.
[261] Didier Rognan,et al. Protein‐based virtual screening of chemical databases. II. Are homology models of g‐protein coupled receptors suitable targets? , 2002, Proteins.
[262] S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. , 1994, European journal of pharmacology.
[263] J. Siuciak,et al. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors , 2004, Psychopharmacology.
[264] K. Marder,et al. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. , 1992, Archives of neurology.
[265] M. Millan,et al. Dopamine D3 receptor antagonists as therapeutic agents. , 2005, Drug discovery today.
[266] J. Javitch,et al. A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[267] B Levant,et al. Relative affinities of dopaminergic drugs at dopamine D2 and D3 receptors. , 1995, European journal of pharmacology.
[268] T. Hyde,et al. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[269] B. Westerink,et al. Enantiomers of monohydroxy-2-aminotetralin derivatives and their activity at dopamine autoreceptors as studied by brain dialysis. , 1991, European journal of pharmacology.
[270] R. Mach,et al. Synthesis of 2-(5-bromo-2,3-dimethoxyphenyl)-5-(aminomethyl)-1H-pyrrole analogues and their binding affinities for dopamine D2, D3, and D4 receptors. , 2003, Bioorganic & medicinal chemistry.
[271] M. Reith,et al. A novel series of hybrid compounds derived by combining 2-aminotetralin and piperazine fragments: binding activity at D2 and D3 receptors. , 2002, Bioorganic & medicinal chemistry letters.
[272] K. Svensson,et al. Effects of dopamine D3 preferring compounds on conditioned place preference and intracranial self-stimulation in the rat , 2005, Journal of Neural Transmission / General Section JNT.
[273] K. Svensson,et al. Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 2. Effects of 8-amino nitrogen substitution on serotonin receptor binding and pharmacology. , 1995, Journal of medicinal chemistry.
[274] B. Roth,et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.
[275] P. Sokoloff,et al. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization , 2001, Nature.
[276] M. Piercey,et al. Pharmacology of U-91356A, an agonist for the dopamine D2 receptor subtype. , 1996, European journal of pharmacology.
[277] P. Sokoloff,et al. Role of DRD3 in morphine-induced conditioned place preference using drd3-knockout mice , 2004, Neuroreport.
[278] S. Usuda,et al. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds. , 1996, Journal of medicinal chemistry.
[279] J. Clemens,et al. Effects of (8beta)-8-[methylthio)methyl]-6-propylergoline on dopaminergic function and brain dopamine turnover in rats. , 1979, Life sciences.
[280] J. Kebabian,et al. S-(+)-aporphines are not selective for human D3 dopamine receptors , 1994, Cellular and Molecular Neurobiology.
[281] W. Oertel,et al. A Non‐Ergot Dopamine Agonist, Pramipexole, in the Therapy of Advanced Parkinson's Disease: Improvement of Parkinsonian Symptoms and Treatment‐Associated Complications. A Review of Three Studies , 1997 .
[282] J. Hagan,et al. Dopamine D3 Receptor Antagonism Inhibits Cocaine-Seeking and Cocaine-Enhanced Brain Reward in Rats , 2002, The Journal of Neuroscience.
[283] G. Aston-Jones,et al. Behavioural pharmacology: Breaking the chain of addiction , 1999, Nature.
[284] Mark Froimowitz,et al. Homology modeling of the dopamine D2 receptor and its testing by docking of agonists and tricyclic antagonists. , 1994, Journal of medicinal chemistry.
[285] Stereocontrolled dopamine receptor binding and subtype selectivity of clebopride analogues synthesized from aspartic acid. , 2003, Bioorganic & medicinal chemistry letters.
[286] R. Beninger,et al. A dopamine D3 receptor partial agonist blocks the expression of conditioned activity , 2002, Neuroreport.
[287] P. Sokoloff,et al. Role of the dopamine D3 receptor in reactivity to cocaine‐associated cues in mice , 2002, The European journal of neuroscience.
[288] P. Sokoloff,et al. N-(ω-(4-(2-Methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as Dopamine D2 and D3 Receptor Ligands , 2003 .
[289] M. Williams,et al. A pharmacological comparison of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl)piperidine with (3-PPP) selected dopamine agonists. , 1982, The Journal of pharmacology and experimental therapeutics.
[290] Dopamine D3 Receptor Ligands with Antagonist Properties , 2002, Chembiochem : a European journal of chemical biology.
[291] K. Thewlis,et al. A novel series of 2-aminotetralins with high affinity and selectivity for the dopamine D3 receptor , 1997 .
[292] M. Caron,et al. Recent advances in the molecular biology of dopamine receptors. , 1993, Annual review of neuroscience.
[293] C. Humblet,et al. G-Protein coupled receptors: models, mutagenesis, and drug design. , 1998, Journal of medicinal chemistry.
[294] R. Mach,et al. Conformationally-flexible benzamide analogues as dopamine D3 and σ2 receptor ligands , 2004 .
[295] Robert H Mach,et al. Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. , 2005, Bioorganic & medicinal chemistry.
[296] D. Sibley,et al. Molecular biology of dopamine receptors. , 1992, Trends in pharmacological sciences.
[297] A. Zapata,et al. Selective D3 receptor agonist effects of (+)-PD 128907 on dialysate dopamine at low doses , 2001, Neuropharmacology.
[298] P. Gmeiner,et al. Enantiospecific synthesis and receptor binding of novel dopamine receptor ligands employing natural 4-hydroxyproline as a practical and flexible building block , 2003 .
[299] J. Hagan,et al. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells , 1999, British journal of pharmacology.
[300] P. Sokoloff,et al. Dopamine D3 receptor ligands modulate the acquisition of morphine-conditioned place preference , 2004, Psychopharmacology.
[301] G. Riley,et al. 2-[(substituted)phenyl]-5-[1-(2-phenylazacycloheptyl)methyl]-1H-pyrroles with high affinity and selectivity for the dopamine D3 receptor , 1997 .
[302] G. Gessa,et al. (-)S amisulpride binds with high affinity to cloned dopamine D(3) and D(2) receptors. , 2001, European journal of pharmacology.
[303] D. Sibley,et al. Chimeric D2/D3 dopamine receptor coupling to adenylyl cyclase. , 1997, Biochemical and biophysical research communications.
[304] M. Millan,et al. Modulation of mesolimbic dopamine release by the selective dopamine D3 receptor antagonist, (+)-S 14297. , 1994, European journal of pharmacology.
[305] Lars Farde,et al. Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907 , 1996, Psychopharmacology.
[306] C. Le Bihan,et al. Respective roles of dopamine D2 and D3 receptors in food-seeking behaviour in rats , 2003, Psychopharmacology.
[307] A. Argiolas,et al. The neuropharmacology of yawning. , 1998, European journal of pharmacology.
[308] Effects of ropinirole on motor behavior in MPTP-treated common marmosets , 2000, Pharmacology Biochemistry and Behavior.
[309] Z. Vogel,et al. Adenylyl Cyclase Interaction with the D2 Dopamine Receptor Family; Differential Coupling to Gi, Gz, and Gs , 1999, Cellular and Molecular Neurobiology.
[310] I. Laszlovszky,et al. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats , 2005, Psychopharmacology.
[311] A. Markham,et al. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. , 1998, Drugs & aging.
[312] M. Reith,et al. Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors. , 2004, Bioorganic & medicinal chemistry.
[313] D. Helmeste,et al. Dopamine D4 receptors. , 2000, Japanese journal of pharmacology.
[314] M. Millan,et al. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. , 2000, The Journal of pharmacology and experimental therapeutics.
[315] P. Novak,et al. Pramipexole: a nonergot dopamine agonist as drug therapy in Parkinson’s disease , 2001, Expert review of neurotherapeutics.
[316] J. Hagan,et al. Anxiolytic profile of ropinirole in the rat, mouse and common marmoset , 2000, Psychopharmacology.
[317] M. Millan,et al. Discriminative stimulus properties of the dopamine D3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D3 versus D2 receptors , 2000, Neuropharmacology.
[318] H. Wikström,et al. Thiophene analogs of naphthoxazines and 2-aminotetralins: bioisosteres with improved relative oral bioavailability, as compared to 5-OH-DPAT. , 2000, European journal of pharmacology.
[319] S. Hjorth,et al. N-Alkylated 2-aminotetralins: central dopamine-receptor stimulating activity. , 1979, Journal of medicinal chemistry.
[320] L. Snyder,et al. Alternative transcripts of the rat and human dopamine D3 receptor. , 1991, Biochemical and biophysical research communications.
[321] M. Millan,et al. Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate , 2004, Experimental Neurology.
[322] D. Jacobowitz,et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[323] A. Carlsson,et al. Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships. , 1994, Journal of medicinal chemistry.
[324] R. Mach,et al. Synthesis of 2-(2,3-dimethoxyphenyl)-4-(aminomethyl)imidazole analogues and their binding affinities for dopamine D(2) and D(3) receptors. , 2001, Bioorganic & medicinal chemistry.
[325] H. Wikström,et al. 2-aminotetralin-derived substituted benzamides with mixed dopamine D2, D3, and serotonin 5-HT1A receptor binding properties: a novel class of potential atypical antipsychotic agents. , 1998, Bioorganic & medicinal chemistry.
[326] K. Wicke,et al. The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors. , 2001, European journal of pharmacology.
[327] D. Sibley,et al. Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. , 1995, European journal of pharmacology.
[328] D. Middlemiss,et al. Pharmacological characterization of extracellular acidification rate responses in human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells , 1999, British journal of pharmacology.
[329] J. Legeai,et al. Synthèse de dérivés aminés du tétrahydro-4,5,6,7 benzothiazole. I: Amines et N-méthylamines en positions 4, 5, 6 et 7 à activité dopaminergique centrale , 1984 .
[330] M. P. Turpin,et al. Novel 6-substituted 2-aminotetralins with potent and selective affinity for the dopamine D3 receptor , 1996 .
[331] H. Kung,et al. [125I](S)-trans-7-OH-PIPAT: a potential spect imaging agent for sigma binding sites. , 1994, Life sciences.
[332] J. Ballesteros,et al. A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice. , 1998, Biochemistry.
[333] J. Hagan,et al. Acute administration of the selective D3 receptor antagonist SB‐277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats , 2003, Synapse.
[334] M. E. Lajiness,et al. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. , 1994, Molecular pharmacology.
[335] Angelo Bifone,et al. Selective dopamine D3 receptor antagonist SB‐277011‐A potentiates phMRI response to acute amphetamine challenge in the rat brain , 2004, Synapse.
[336] M. Nader,et al. The effects of benzamide analogues on cocaine self-administration in rhesus monkeys , 1999, Psychopharmacology.
[337] O. Rascol,et al. Treatment of Parkinson's disease should begin with a dopamine agonist , 1999, Movement disorders : official journal of the Movement Disorder Society.
[338] M. Millan,et al. Activation of dopamine D3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. , 1995, European journal of pharmacology.
[339] B. Levant,et al. Differential distribution of D3 dopamine receptors in the brains of several mammalian species , 1998, Brain Research.
[340] M. E. Lajiness,et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. , 1995, European journal of pharmacology.
[341] I. Gyertyán,et al. Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference , 2003, Neuroreport.
[342] F. Boeckler,et al. Fancy bioisosteres: metallocene-derived G-protein-coupled receptor ligands with subnanomolar binding affinity and novel selectivity profiles. , 2005, Journal of medicinal chemistry.
[343] J. Ballesteros,et al. Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: contributions of the second membrane-spanning segment. , 1999, Biochemistry.
[344] J. Waddington,et al. Heterogeneity of behavioural profile between three new putative selective D3 dopamine receptor antagonists using an ethologically based approach , 1998, Psychopharmacology.
[345] E. Bézard,et al. Effect of the D3 Dopamine Receptor Partial Agonist BP897 [N-[4-(4-(2-Methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on l-3,4-Dihydroxyphenylalanine-Induced Dyskinesias and Parkinsonism in Squirrel Monkeys , 2004, Journal of Pharmacology and Experimental Therapeutics.
[346] B. Everitt,et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist , 1999, Nature.
[347] S. Fuchs,et al. A novel short isoform of the D3 dopamine receptor generated by alternative splicing in the third cytoplasmic loop. , 1993, The Journal of biological chemistry.
[348] Peter Gmeiner,et al. Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand-receptor complexes. , 2005, Journal of medicinal chemistry.
[349] M. Martres,et al. Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[350] R. Todd,et al. Morphogenic potentials of D2, D3, and D4 dopamine receptors revealed in transfected neuronal cell lines. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[351] P. Carvey,et al. Mechanisms of action of pramipexole: Putative neuroprotective effects , 2001 .
[352] F. Mcdowell,et al. “Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease , 1991, Neurology.
[353] Niall Quinn,et al. Young onset Parkinson's disease , 1987, Movement disorders : official journal of the Movement Disorder Society.
[354] E. Lehr. Potential antidepressant properties of pramipexole detected in locomotor and operant behavioral investigations in mice , 2002, Psychopharmacology.
[355] G. Hanson,et al. Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration. , 2003, European journal of pharmacology.
[356] J. Brotchie,et al. Ropinirole versus l-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia , 2004, Experimental Neurology.
[357] G. F. Lundell,et al. Synthesis of 4-substituted 2H-naphth[1,2-b]-1,4-oxazines, a new class of dopamine agonists. , 1984, Journal of medicinal chemistry.
[358] P. Sokoloff,et al. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. , 1995, The Journal of pharmacology and experimental therapeutics.
[359] R. A. Fuchs,et al. Increases in Dopamine D3 Receptor Binding in Rats Receiving a Cocaine Challenge at Various Time Points after Cocaine Self-Administration: Implications for Cocaine-Seeking Behavior , 2004, Neuropsychopharmacology.
[360] J. Hagan,et al. Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist. , 2003, Journal of medicinal chemistry.
[361] Erin E. Carlson,et al. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. , 2005, Journal of medicinal chemistry.
[362] A. Fink-Jensen,et al. Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI. , 1998, European journal of pharmacology.
[363] R. Pahwa,et al. Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N‐0923 TDS: A double‐blind, placebo‐controlled study , 2001 .
[364] M. Martres,et al. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[365] J. Joyce,et al. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[366] A. Davis,et al. Hydrogen Bonding, Hydrophobic Interactions, and Failure of the Rigid Receptor Hypothesis. , 1999, Angewandte Chemie.
[367] M. Piercey,et al. Pramipexole — a new dopamine agonist for the treatment of Parkinson's disease , 1999, Journal of the Neurological Sciences.
[368] Harald Hübner,et al. Fancy bioisosteres: synthesis and dopaminergic properties of the endiyne FAUC 88 as a novel non-aromatic D3 agonist. , 2005, Bioorganic & medicinal chemistry.
[369] Bruno Giros,et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.
[370] A. Schapira. Dopamine agonists and neuroprotection in Parkinson's disease. , 2002, European journal of neurology.
[371] J. Belluzzi,et al. N‐0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.
[372] N. Mohell,et al. Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding. , 1998, The Journal of pharmacology and experimental therapeutics.
[373] J. Joyce,et al. D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: Influence of withdrawal period , 2001, Synapse.
[374] F. J. White,et al. Dopamine D3 receptor mutant and wild‐type mice exhibit identical responses to putative D3 receptor‐selective agonists and antagonists , 1999, Synapse.
[375] J. Meador-Woodruff. Update on dopamine receptors. , 1994, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.
[376] H. Kung,et al. Synthesis of (R,S)-2'-trans-7-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'- propenyl)-amino]tetralin (trans-7-OH-PIPAT): a new D3 dopamine receptor ligand. , 1993, Journal of medicinal chemistry.
[377] Manfred Burghammer,et al. Structure of bovine rhodopsin in a trigonal crystal form. , 2003, Journal of molecular biology.
[378] Glen L Alberts,et al. Contributions of cysteine 114 of the human D3 dopamine receptor to ligand binding and sensitivity to external oxidizing agents , 1998, British journal of pharmacology.
[379] M. P. Turpin,et al. Mapping of dopamine D3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki Forest virus system. , 1998, Journal of receptor and signal transduction research.
[380] M. Caron,et al. Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor. , 1997, Molecular pharmacology.
[381] In Vivo Occupancy of D2Dopamine Receptors by Nafadotride , 1997, Neuropsychopharmacology.
[382] H. Sahraei,et al. Involvement of Dopamine Receptors of the Dorsal Hippocampus on the Acquisition and Expression of Morphine-Induced Place Preference in Rats , 2003, Journal of psychopharmacology.
[383] P. Sokoloff,et al. The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and d -amphetamine and is not self-administered , 2001, Behavioural pharmacology.
[384] C. Reavill,et al. Comparative Pharmacological Study of Ropinirole (SKF‐101468) and its Metabolites in Rats , 2000, The Journal of pharmacy and pharmacology.
[385] Jonathan A Javitch,et al. The Ants Go Marching Two by Two: Oligomeric Structure of G-Protein-Coupled Receptors , 2004, Molecular Pharmacology.
[386] S. Franklin,et al. Discriminative stimulus properties of the dopamine D3 antagonist PNU-99194A , 1998, Psychopharmacology.
[387] J. Cannon,et al. Centrally acting emetics. 10. Rigid dopamine congeners derived from octahydrobenzo[f]quinoline. , 1976, Journal of medicinal chemistry.
[388] Christina Z Floresca,et al. Dopamine Receptor Microdomains Involved in Molecular Recognition and the Regulation of Drug Affinity and Function , 2004, Journal of receptor and signal transduction research.